A‐to‐I RNA editing by ADAR and its therapeutic applications: From viral infections to cancer immunotherapy
WIREs RNA · 2024-01 · 15 (1)
DOI: 10.1002/wrna.1817 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs RNA, online erschienen am 17.09.2023. Verfasst von Rohini Datta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Stanford University, Stanford, California, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
ADAR deaminases catalyze adenosine‐to‐inosine (A‐to‐I) editing on double‐stranded RNA (dsRNA) substrates that regulate an umbrella of biological processes. One of the two catalytically active ADAR enzymes, ADAR1, plays a major role in innate immune responses by suppression of RNA sensing pathways which are orchestrated through the ADAR1‐dsRNA‐MDA5 axis. Unedited immunogenic dsRNA substrates are potent ligands for the cellular sensor MDA5. Upon activation, MDA5 leads to the induction of interferons and expression of hundreds of interferon‐stimulated genes with potent antiviral activity. In this way, ADAR1 acts as a gatekeeper of the RNA sensing pathway by striking a fine balance between innate antiviral responses and prevention of autoimmunity. Reduced editing of immunogenic dsRNA by ADAR1 is strongly linked to the development of common autoimmune and inflammatory diseases. In viral infections, ADAR1 exhibits both antiviral and proviral effects. This is modulated by both editing‐dependent and editing‐independent functions, such as PKR antagonism. Several A‐to‐I RNA editing events have been identified in viruses, including in the insidious viral pathogen, SARS‐CoV‐2 which regulates viral fitness and infectivity, and could play a role in shaping viral evolution. Furthermore, ADAR1 is an attractive target for immuno‐oncology therapy. Overexpression of ADAR1 and increased dsRNA editing have been observed in several human cancers. Silencing ADAR1, especially in cancers that are refractory to immune checkpoint inhibitors, is a promising therapeutic strategy for cancer immunotherapy in conjunction with epigenetic therapy. The mechanistic understanding of dsRNA editing by ADAR1 and dsRNA sensing by MDA5 and PKR holds great potential for therapeutic applications. This article is categorized under: RNA Processing > RNA Editing and Modification RNA in Disease and Development > RNA in Disease
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics, Stanford University, Stanford, California, USA.
ORCID-Profile: Rohini Datta, Jin Billy Li
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Datta, R., Adamska, J. Z., Bhate, A., & Li, J. B. (2024). A‐to‐I RNA editing by ADAR and its therapeutic applications: From viral infections to cancer immunotherapy. WIREs RNA, 15(1). https://doi.org/10.1002/wrna.1817
Vancouver
Datta R, Adamska JZ, Bhate A, Li JB. A‐to‐I RNA editing by ADAR and its therapeutic applications: From viral infections to cancer immunotherapy. WIREs RNA. 2024;15(1). doi:10.1002/wrna.1817
BibTeX
@article{Datta2024,
author = {Datta, Rohini and Adamska, Julia Z and Bhate, Amruta and Li, Jin Billy},
title = {A‐to‐I RNA editing by ADAR and its therapeutic applications: From viral infections to cancer immunotherapy},
journal = {WIREs RNA},
year = {2024},
volume = {15},
number = {1},
doi = {10.1002/wrna.1817}
}
EUVIMED